Sophie Cousin

4.9k total citations
126 papers, 1.9k citations indexed

About

Sophie Cousin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Sophie Cousin has authored 126 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Oncology, 66 papers in Pulmonary and Respiratory Medicine and 25 papers in Molecular Biology. Recurrent topics in Sophie Cousin's work include Sarcoma Diagnosis and Treatment (29 papers), Cancer Immunotherapy and Biomarkers (25 papers) and Lung Cancer Treatments and Mutations (21 papers). Sophie Cousin is often cited by papers focused on Sarcoma Diagnosis and Treatment (29 papers), Cancer Immunotherapy and Biomarkers (25 papers) and Lung Cancer Treatments and Mutations (21 papers). Sophie Cousin collaborates with scholars based in France, Spain and Italy. Sophie Cousin's co-authors include Antoîne Italiano, Alban Bessede, Nicolas Penel, Maud Toulmonde, Florent Peyraud, Jean‐Yves Blay, Jean‐Philippe Guégan, François Le Loarer, Michèle Kind and Emmanuelle Bompas and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Sophie Cousin

118 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sophie Cousin France	21	1.2k	862	450	320	226	126	1.9k
Shinzo Takamori Japan	22	1.3k 1.1×	1.2k 1.4×	493 1.1×	455 1.4×	192 0.8×	106	2.6k
Audrey Mansuet‐Lupo France	22	981 0.8×	722 0.8×	326 0.7×	462 1.4×	142 0.6×	64	1.8k
Maud Toulmonde France	23	1.2k 1.0×	1.3k 1.5×	346 0.8×	689 2.2×	391 1.7×	113	2.5k
Christine Chevreau France	18	813 0.7×	509 0.6×	186 0.4×	199 0.6×	251 1.1×	59	1.4k
Yusri Elsayed United States	22	1.1k 0.9×	606 0.7×	422 0.9×	1.1k 3.3×	235 1.0×	51	2.4k
Lorena Incorvaia Italy	24	910 0.8×	675 0.8×	247 0.5×	602 1.9×	147 0.7×	113	1.9k
Hussein Tawbi United States	24	1.1k 0.9×	694 0.8×	382 0.8×	739 2.3×	177 0.8×	108	2.0k
Marine Gilabert France	22	910 0.8×	422 0.5×	213 0.5×	395 1.2×	231 1.0×	73	1.8k
Giovanni Fucà Italy	23	1.2k 1.0×	549 0.6×	293 0.7×	382 1.2×	133 0.6×	87	1.8k
Giuseppe Badalamenti Italy	25	1.0k 0.8×	764 0.9×	182 0.4×	621 1.9×	212 0.9×	144	2.3k

Countries citing papers authored by Sophie Cousin

Since Specialization

Citations

This map shows the geographic impact of Sophie Cousin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sophie Cousin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sophie Cousin more than expected).

Fields of papers citing papers by Sophie Cousin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sophie Cousin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sophie Cousin. The network helps show where Sophie Cousin may publish in the future.

Co-authorship network of co-authors of Sophie Cousin

This figure shows the co-authorship network connecting the top 25 collaborators of Sophie Cousin. A scholar is included among the top collaborators of Sophie Cousin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sophie Cousin. Sophie Cousin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Remón, Jordi, Paolo Bironzo, Nicolas Girard, et al.. (2025). Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. The Lancet Oncology. 26(9). 1215–1226. 1 indexed citations

Italiano, Antoine, Isabelle Soubeyran, Emmanuel Khalifa, et al.. (2024). Extensive molecular profiling of KRAS wild-type as compared to KRAS mutated pancreatic ductal adenocarcinoma on 318 patients. European Journal of Cancer. 216. 115197–115197. 1 indexed citations

Planchard, David, Nathalie Cozic, Marie Wislez, et al.. (2024). ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome.. Journal of Clinical Oncology. 42(16_suppl). 8501–8501. 6 indexed citations

Masip, J. Remon, Paolo Bironzo, N. Girard, et al.. (2024). LBA83 PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma. Annals of Oncology. 35. S1270–S1270. 3 indexed citations

Vieito, María, Ezra Y. Rosen, Jordi Rodón, et al.. (2024). 160TiP A phase I/II study of CFT1946, a novel BIDAC degrader targeting mutant BRAF V600 solid tumors including metastatic colorectal cancer (CRC) in combination with cetuximab. Annals of Oncology. 35. S71–S72.

Palussière, Jean, Laura Leroy, Benjamin Bonhomme, et al.. (2024). Single- and multi-site radiomics may improve overall survival prediction for patients with metastatic lung adenocarcinoma. Diagnostic and Interventional Imaging. 105(11). 439–452. 4 indexed citations

Palussière, Jean, Laura Leroy, Benjamin Bonhomme, et al.. (2024). Enhancing Immunotherapy Response Prediction in Metastatic Lung Adenocarcinoma: Leveraging Shallow and Deep Learning with CT-Based Radiomics across Single and Multiple Tumor Sites. Cancers. 16(13). 2491–2491. 1 indexed citations

Vieito, María, Ezra Y. Rosen, Jordi Rodón, et al.. (2024). 612O Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors. Annals of Oncology. 35. S490–S491. 3 indexed citations

Cousin, Sophie, Luis Paz‐Ares, Andrea Fülöp, et al.. (2023). Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.. Journal of Clinical Oncology. 41(16_suppl). 8591–8591. 1 indexed citations

10.

Palmieri, Lola‐Jade, Sophie Cousin, Mariella Spalato Ceruso, et al.. (2023). Targeting EZH2 to overcome the resistance to immunotherapy in microsatellite stable colorectal cancer: Results from the CAIRE study.. Journal of Clinical Oncology. 41(16_suppl). 3599–3599. 2 indexed citations

11.

Abdeddaim, Cyril, Sophie Cousin, Carlos Gomez‐Roca, et al.. (2023). 758P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial. Annals of Oncology. 34. S518–S518. 1 indexed citations

12.

Bessede, Alban, Florent Peyraud, Sylvestre Le Moulec, et al.. (2023). Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer. Clinical Cancer Research. 29(23). 4883–4893. 12 indexed citations

13.

Borel, Christian, François Ghiringhelli, Frédéric Bigot, et al.. (2023). 752P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial. Annals of Oncology. 34. S515–S516. 1 indexed citations

14.

Cousin, Sophie, Carine Bellera, Rastilav Bahleda, et al.. (2022). 1494P Regomune - a phase II study of regorafenib + avelumab in solid tumors: Results of the soft tissue sarcoma (STS) cohort. Annals of Oncology. 33. S1230–S1230. 3 indexed citations

15.

Cousin, Sophie, Coralie Cantarel, Jean‐Philippe Guégan, et al.. (2021). Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial. Clinical Cancer Research. 27(8). 2139–2147. 95 indexed citations

16.

Remón, Jordi, Nicolas Girard, Silvia Novello, et al.. (2021). PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clinical Lung Cancer. 23(3). e243–e246. 24 indexed citations

17.

Schöffski, Patrick, Maud Toulmonde, Anna Estival, et al.. (2021). Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA”. European Journal of Cancer. 152. 26–40. 10 indexed citations

18.

Cesne, Axel Le, Perrine Marec‐Bérard, Jean‐Yves Blay, et al.. (2019). Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. European Journal of Cancer. 119. 151–157. 114 indexed citations

19.

Crombé, Amandine, François Le Loarer, N. Alberti, et al.. (2018). Homogeneous myxoid liposarcomas mimicking cysts on MRI: A challenging diagnosis. European Journal of Radiology. 102. 41–48. 8 indexed citations

20.

Cousin, Sophie, et al.. (2017). Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine (gem) in patients (pts) with refractory solid tumors. Annals of Oncology. 28. v125–v125. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact